AG-858
information and resources from the National Cancer Institute
NCI Thesaurus | AG-858
A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. NCI Thesaurus | AG-858
A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.
|
|
|
|
news articles
Antigenics Updates Business Strategy and Outlines Timeline for the ... Dec 6, 2005
Genetic Engineering News, Antigenics' portfolio of investigational products also includes AG-858 (HSPPC-70), a patient-specific cancer vaccine in Phase 2 development; two liposomal ...
Antigenics Updates Business Strategy and Outlines Timeline for the ... Dec 6, 2005
Finanzen.net, ...in severalindications, including renal cell carcinoma and metastatic melanoma.Antigenics' portfolio of investigational products also includes AG-858(HSPPC-70 ...
Antigenics Updates Business Strategy and Outlines Timeline for the ... Dec 6, 2005
Genetic Engineering News, Antigenics' portfolio of investigational products also includes AG-858 (HSPPC-70), a patient-specific cancer vaccine in Phase 2 development; two liposomal ...
Antigenics Updates Business Strategy and Outlines Timeline for the ... Dec 6, 2005
Finanzen.net, ...in severalindications, including renal cell carcinoma and metastatic melanoma.Antigenics' portfolio of investigational products also includes AG-858(HSPPC-70 ...
|
|
